Xu et al. reported the serum autoantibody panel (p53, MMP-7, HSP70, Prx VI and Bmi-1) could distinguish early-stage ESCC patients (n = 76) from normal controls (n = 134) with sensitivity of 45% and specificity of 96% in a validation cohort [13]. Here, TP53 is linked to esophageal squamous cell carcinoma.